Therapeutic drug monitoring, mucosal healing, deep remission: The path to nirvana in crohn's disease?

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 3, 2014, Pages 432-433

  Moss, Alan C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; MALE; POLYETHYLENE GLYCOLS;

EID: 84893981377     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.12.022     Document Type: Editorial

References (17)

1. Rutgeerts P., Vermeire S., Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?. Gut 2007, 56:453-455.
2. Baert F., Moortgat L., Van Assche G., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138:463-468.
3. Maser E.A., Villela R., Silverberg M.S., et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
4. Colombel J.F., Rutgeerts P.J., Sandborn W.J., et al. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014, 12:414-422.
5. Colombel J.F., Louis E., Peyrin-Biroulet L., et al. Deep remission: a new concept?. Dig Dis 2012, 30(suppl 3):107-111.
6. Farrokhyar F., Marshall J.K., Easterbrook B., et al. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis 2006, 12:38-46.
7. Lahiff C., Safaie P., Awais A., et al. The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2013, 37:786-794.
8. Colombel J.F., Sandborn W.J., Allez M., et al. Association between plasma concentrations of certolizumab pegol andendoscopic outcomes of patients with Crohn's disease. ClinGastroenterol Hepatol 2014, 12:423-431.
9. Hebuterne X., Lemann M., Bouhnik Y., et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013, 62:201-208.
10. Moore C., Vaughn B., Moss A.C. Analysis of reporting standards of serum anti-TNF levels in patients with IBD. Inflamm Bowel Dis 2013, 19(suppl 1):P080.
11. Brandse J., Wildenberg M., de Bruyn J., et al. Fecal loss of infliximab as a cause of lack of response in severe inflammatory bowel disease. Gastroenterology 2013, 142(5 suppl 1):S-36.
12. Fasanmade A.A., Adedokun O.J., Blank M., et al. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther 2011, 33:946-964.
13. Hamalainen A., Sipponen T., Kolho K.L. Serum infliximab concentrations in pediatric inflammatory bowel disease. Scand J Gastroenterol 2013, 48:35-41.
14. Feagan B.G. Novel infliximab and antibody-to-infliximab assays are predictive of disease activity in patients with Crohn's disease. Gastroenterology 2012, 142(5 suppl 1):A565.
15. Vande C.N., Buurman D.J., Sturkenboom M.G., et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison ofthree different assays. Aliment Pharmacol Ther 2012, 36:765-771.
16. Bouguen G., Levesque B.G., Pola S., et al. Endoscopic assessment and treating to target increase thelikelihood of mucosal healing in patients with Crohn's disease. Clin Gastroenterol Hepatol 2013 Nov 15, [Epub ahead of print].
17. Reinisch W., Colombel J.F., Sandborn W.J., et al. Infliximab serum trough level and CRP change are associated with corticosteroid-free remission in Crohn's disease: a post-hoc analysis of the sonic trial. Gut 2012, 61(suppl 3):A170.